Which TKI should I use in a newly diagnosed CML patient? When should I switch therapy? How and how often should I monitor disease? Is TKI discontinuation a realistic goal, and if so, how do we get there? In CML there is a near embarrassment of riches in the TKI options, all of which are excellent drugs, with specific advantages and disadvantages. Treatment response can be done relatively easily. We will develop a common sense plan to optimize therapy based on patient characteristics and treatment goals.